CNS PharmaceuticalsCNS PharmaceuticalsCNS Pharmaceuticals
  • Brain
    • Glioblastoma
    • Anthracyclines
    • Blood Brain Barrier
  • Technology
    • Berubicin
    • Pipeline
  • Team
    • Management
    • Board
  • About Us
  • Contact
  • Investors
  • Sign Up

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Analyst Coverage
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

Jan 07, 2022 8:05am EST

CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Jan 06, 2022 7:00am EST

CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Dec 02, 2021 8:35am EST

CNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event

Nov 16, 2021 8:00am EST

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme

Oct 11, 2021 8:00am EDT

CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)

Sep 30, 2021 8:05am EDT

CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook

Aug 13, 2021 8:05am EDT

CNS Pharmaceuticals Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM

Jul 01, 2021 9:05am EDT

FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

Jun 29, 2021 8:35am EDT

CNS Pharmaceuticals Announces Inclusion in the Russell 2000® Index

Jun 17, 2021 9:05am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...12
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    © 2023 CNS Pharmaceuticals. All Rights Reserved, CNS Pharma

    • Brain
      • Glioblastoma
      • Anthracyclines
      • Blood Brain Barrier
    • Technology
      • Berubicin
      • Pipeline
    • Team
      • Management
      • Board
    • About Us
    • Contact
    • Investors
    • Sign Up